Most biotech companies are chasing the same hot tumors, but IN8bio is tackling the immunologically 'cold' cancers that current therapies can't touch. They're doing it with a novel, off-the-shelf approach using genetically modified gamma-delta T cells.

"They're not just another cell therapy company—they're engineering a new class of 'off-the-shelf' immune cells to hunt down cancers that have evaded standard treatments."

The real story isn't in the raw traffic numbers, but in the specificity of their mission. By focusing on gamma-delta T cells—a less common but potent subset of T cells—they're betting on a platform that can address both solid tumors and hematological cancers. This isn't incremental improvement; it's a strategic pivot away from the crowded alpha-beta T cell space.

• Novel Platform: Uses genetically modified gamma-delta T cells, not the more common CAR-T.
• Off-the-Shelf Approach: Aims for allogeneic (donor-derived) therapies, reducing wait times and costs.
• Cold Tumor Focus: Targets immunologically 'cold' cancers resistant to current immunotherapies.